StockData
Labcorp Holdings Inc. logo

Labcorp Holdings Inc. (LH) stock

LHNYSEServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 11/303% above fair value
$368.16+7.91 (+2.20%)

Close on Oct 29, 2026Market cap $29.86BP/E 30.2Yield 0.78%

Earnings

Labcorp's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 16, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$3.81B
+7.0% on a year earlier
Adjusted EPS, Q3 FY2026
$4.78
$4.18 a year earlier
Latest guidance
Issued
Oct 28, 2026 · 3 items

Quarterly results

Revenue and earnings per share from each of Labcorp's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q4 FY2026ended Dec 31, 2026Feb 16, 2027Expected–––––
Q3 FY2026ended Sep 30, 2026Oct 28, 2026before the open$3.81B+7.0%$3.22$4.78Release
Q2 FY2026ended Jun 30, 2026Jul 30, 2026before the open$3.73B+5.7%$3.64$4.99Release
Q1 FY2026ended Mar 31, 2026Apr 30, 2026before the open$3.54B+5.7%$3.35$4.25Release
Q4 FY2025ended Dec 31, 2025Feb 17, 2026before the open$3.52B+5.7%$1.98$4.07Release
Q3 FY2025ended Sep 30, 2025Oct 28, 2025before the open$3.56B+8.5%$3.12$4.18Release
Q2 FY2025ended Jun 30, 2025Jul 24, 2025before the open$3.53B+9.6%$2.84$4.35Release
Q1 FY2025ended Mar 31, 2025Apr 29, 2025before the open$3.35B+5.3%$2.52$3.84Release
Q4 FY2024ended Dec 31, 2024Feb 6, 2025before the open$3.33B+9.9%$1.70$3.45Release
Q3 FY2024ended Sep 30, 2024Oct 24, 2024before the open$3.28B+7.2%$2.00$3.50Release
Q2 FY2024ended Jun 30, 2024Aug 1, 2024before the open$3.22B+6.3%$2.43$3.94Release
Q1 FY2024ended Mar 31, 2024Apr 25, 2024before the open$3.18B-15.9%$2.69$3.68Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Labcorp's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
GrowthFY2026+5.4% – +6.3%+5% – +6.1%RaisedJul 30, 2026
Labcorp EnterpriseGAAPFY2026$14.78B – $14.89B–NewOct 28, 2026
Labcorp EnterpriseFY2026$14.71B – $14.83B$14.65B – $14.80BRaisedJul 30, 2026
Adjusted EPSnon-GAAPFY2026$18.30 – $18.70–NewOct 28, 2026
Adjusted EPSnon-GAAPFY2026$18.10 – $18.55$17.70 – $18.35RaisedJul 30, 2026
Free Cash Flownon-GAAPFY2026$1.24B – $1.36B–NewOct 28, 2026
Free Cash Flownon-GAAPFY2026$1.24B – $1.36B$1.24B – $1.36BReaffirmedJul 30, 2026

Guidance vs results

The last range Labcorp gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2025Adjusted EPS range$16.15 – $16.50$16.44Σ4QWithin range
FY2025Revenue growth+7.4% – +8%+7.3%Σ4QBelow range

Guidance history

Every forecast Labcorp put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Oct 28, 2026Adjusted EPSFY2026$18.30 – $18.70New
Oct 28, 2026Free Cash FlowFY2026$1.24B – $1.36BNew
Oct 28, 2026Labcorp EnterpriseFY2026$14.78B – $14.89BNew
Jul 30, 2026Adjusted EPSFY2026$18.10 – $18.55Raised
Jul 30, 2026Free Cash FlowFY2026$1.24B – $1.36BReaffirmed
Jul 30, 2026GrowthFY2026+5.4% – +6.3%Raised
Jul 30, 2026Diagnostics Laboratories GrowthFY2026+5.3% – +6%Lowered
Jul 30, 2026Biopharma Laboratory Services GrowthFY2026+5.5% – +6.5%Raised
Jul 30, 2026Labcorp EnterpriseFY2026$14.71B – $14.83BRaised
Jul 30, 2026Diagnostics LaboratoriesFY2026$11.45B – $11.53BLowered
Jul 30, 2026Biopharma Laboratory ServicesFY2026$3.27B – $3.30BLowered
Apr 30, 2026Adjusted EPSFY2026$17.70 – $18.35Raised
Apr 30, 2026Free Cash FlowFY2026$1.24B – $1.36BReaffirmed
Apr 30, 2026Revenue guidanceFY2026+5% – +6.1%Raised
Apr 30, 2026Growth (3)FY2026+5.1% – +5.9%Narrowed
Apr 30, 2026Growth (3)FY2026+3.8% – +5.4%Lowered
Apr 30, 2026Labcorp EnterpriseFY2026$14.65B – $14.80BRaised
Apr 30, 2026Diagnostics LaboratoriesFY2026$11.43B – $11.52BLowered
Apr 30, 2026Biopharma Laboratory ServicesFY2026$3.22B – $3.27BLowered
Feb 17, 2026Adjusted EPSFY2026$17.55 – $18.25New

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Labcorp filed with the SEC as exhibits to Form 8-K or 6-K

  1. Labcorp Reports Strong 2026 Third Quarter Results; Raises Full Year 2026 Guidance
    Results
  2. 8-K exhibit EX-99.1
    Update
  3. Labcorp to Announce Third Quarter Financial Results on October 28, 2026
    Update
  4. Labcorp Highlights Strategic Priorities Driving Durable Growth
    Update
  5. 8-K exhibit EX-99.2
    Update
  6. Labcorp to Speak at the Morgan Stanley 24th Annual Global Healthcare Conference
    Update
  7. Labcorp to Host Investor Day on September 10, 2026
    Update
  8. Labcorp Announces 2026 Second Quarter Results; Raises Full Year 2026 Guidance
    Results
  9. 8-K exhibit EX-99.1
    Update
  10. Labcorp to Announce Second Quarter Financial Results on July 30, 2026
    Update
  11. Labcorp to Present at the Jefferies Global Healthcare Conference
    Update
  12. Labcorp Announces 2026 First Quarter Results; Raises Full Year 2026 Guidance
    Results
  13. 8-K exhibit EX-99.1
    Update
  14. Labcorp to Announce First Quarter Financial Results on April 30, 2026
    Update
  15. Labcorp Announces 2025 Fourth Quarter and Full Year Results
    Results